Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing

Laura Testa North America Legal Chronicle
Tagged:

Latham & Watkins represented Arcutis in the transaction.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that it…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Laura Testa

Author: Laura Testa

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here